Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results
Jan 13, 2020
TUCSON, Ariz., Jan. 13, 2020 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter and year ending December 31, 2019. Highlights for the fourth quarter and full-year 2019 are presented below.
2019 Fourth Quarter and Full-Year Financial Highlights
- Commercially contracted instruments were 137 in the fourth quarter and 304 for full-year 2019
- Total revenue for the fourth quarter is expected to be approximately $3.5 million, compared to $1.8 million in the fourth quarter of 2018. For full-year 2019, total revenue is expected to be $9.3 million, compared to $5.7 million for full-year 2018.
- Gross margin is expected to be roughly 50% for full-year 2019
- Net cash used is expected to be approximately $58 million for full-year 2019, resulting in cash on hand of $109 million
Jack Phillips, incoming Chief Executive Officer of Accelerate Diagnostics, Inc, commented, “We are pleased with our overall placement trajectory after doubling our contracted Phenos in 2019 and we remain confident in our outlook for continued strong adoption in 2020. However, our revenue in the fourth quarter fell short of our expectations due to continued delays of multi-site contracted customers going clinically live and beginning to generate consumable revenue. A top near-term priority is successfully implementing our now-reengineered go-live process and ensuring that our customers are able to bring this life-saving technology to their patients as quickly as possible upon adoption of the Pheno.”
- Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes
Oct 03, 2019
- Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies
Sep 18, 2019
- Accelerate Diagnostics Expands Antimicrobials in New CE-Marked Accelerate PhenoTest™ BC kit
Aug 02, 2019